{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-276693","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2026-06-22T11:09:59+00:00","discovered_at":"2026-06-22T11:15:01.243030+00:00","generated_at":"2026-06-22T11:16:23.087810+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TSC-101 Cohort C: 11/14 patients achieved complete donor chimerism; Phase 3 start planned this month","bullets":["11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion; 2 additional patients approaching.","~90% manufacturing success rate (17/19) with commercial-ready process; 14/19 patients received first infusion.","One TP53-mutated AML patient remained in complete donor chimerism 6 months post-HCT.","TSC-101 well-tolerated; safety consistent with Cohort A; company plans to initiate Phase 3 ALLOHA-2 study this month."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-276693","json":"https://secwatch.observer/filing/0001193125-26-276693.json","markdown":"https://secwatch.observer/filing/0001193125-26-276693.md","text":"https://secwatch.observer/filing/0001193125-26-276693.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526276693/0001193125-26-276693-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526276693/d103234d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T11:16:23.087810+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}